An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: Mutagenically separated PCR targeting M184I/V

AIDS Research and Human Retroviruses

Volumn 23, Issue 12, 2007, Pages 1461-1467

  Saeng Aroon, Siriphan ^a   Yoshida, Lay Myint ^b,c   Ariyoshi, Koya ^b   Taguchi, Masataka ^b   Pathipvanich, Panita ^d   Rojanawiwat, Archawin ^a   Matsuda, Masakazu ^c   Kannagi, Mari ^e   Sawanpanyalert, Pathom ^a   Sugiura, Wataru ^c   Auwanit, Wattana ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b NAGASAKI UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d LAMPANG HOSPITAL   (Thailand)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THAILAND; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STAVUDINE; THAILAND;

EID: 37549063042     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0042     Document Type: Article

References (21)

1. UNAIDS: Report on the global AIDS epidemic by Joint United Nations Programme on HIV/AIDS(UNAIDS), Geneva, July, 2004.
2. Kunanusont C, Foy HM, Kreiss JK, Rerks-Ngarm S, Phanuphak P, Raktham S, Pau CP, and Young NL: HIV-1 subtypes and male-to-female transmission in Thailand. Lancet 1995;345:1078-1083.
3. Ou CY, Takebe Y, Weniger BG, Luo CC, Kalish ML, Auwanit W, Yamazaki S, Gayle HD, Young NL, and Schochetman G: Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;341:1171-1174.
4. Wasi C, Herring B, Raktham S, Vanichseni S., Mastro TD, Young NL, Rubsamen-Waigmann H, von Briesen H, Kalish ML, Luo CC, et al.: Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: Evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-849.
5. The Thai Working Group on HIV/AIDS projection: Projections for HIV/AIDS in Thailand: 2000-2020. Karnsana Printing Press, Bangkok, 2001.
6. Pathipvanich P, Ariyoshi K, Rojanawiwat A, Wongchoosie S, Yingseree P, Yoshiike K, Warachit P, and Sawanpanyalert P: Survival benefit from non-highly active antiretroviral therapy in a resource-constrained setting. J Acquir Immune Defic Syndr 2003;32:157-160.
7. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, and Suwanagool S: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: A 24-week study. J Med Assoc Thai 2003;87:760-767.
8. Frater AJ, Chaput CC, Beddows S, Weber JN, and McClure MO: Simple detection of point mutations associated with HIV-1 drug resistance. J Virol Methods 2001;93:145-156.
9. Myint L, Ariyoshi K, Yan H, Frater AJ, Auwanit W, Pathipvanith P, Yamada K, Matsuda M, Chiba T, Fujita K, McClure MO, Weber JN, and Sugiura W: Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (Subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002;46:3861-3868.
10. Johnson V, Brun-Vezinet F, Clotet B, Kuritzkes D, Pillay D, Schapiro J, and Richman D: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
11. Frost S, Nijhuis M, Schuurman R, Boucher C, and Brown A: Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection. J Virol. 2000;74 6262-6268.
12. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, and Wainberg MA: Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1997;25:4532-4536.
13. Rezende LF, Drosopoulos WC, and Prasad VR: The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res 1998;26:3066-3072.
14. Saeng-Aroon S, Wichukchinda N, Myint L, Pathipvanich P, Ariyoshi K, Rojanawiwat A, Matsuda M, Sawanpanyalert P, Sugiura W, and Auwanit W: Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: Role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings. J Acquir Immune Defic Syndr 2004;36:1051-1056.
15. Descamps D, Flandre P, Calvez C, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JB, Pialoux G, Raffi F, and Brun-Vezinet F: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). JAMA 2000;283:205-211.
16. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, and Cameron JM: High-level resistance to (-) enantiomeric 2′-deoxy-3′- thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-2234.
17. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, and Wainberg MA: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-1392.
18. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, and Mellors JW: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
19. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
20. Tisdale M, Kemp SD, Parry NR, and Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-5656.
21. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, et al.: Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995;9:351-357.